Shares of Natco Pharma Ltd rallied 12.5% to touch a day’s high of Rs 932 on 16th February. This happened after the company said it had received approval from the Central Drugs Standard Control Organisation (CDSCO). Consequently, it can manufacture and market generic semaglutide injection in India.
The company said in an exchange filing that it plans to launch the product in the Indian market in March 2026.
Semaglutide is used to treat adults with inadequately controlled type 2 diabetes and is prescribed along with diet and exercise.
Earlier, Natco Pharma had approached the Delhi High Court seeking revocation of Danish drugmaker Novo Nordisk’s patent on semaglutide.
Separately, Dr Reddy’s Laboratories had also moved the Delhi High Court last year under the Patents Act. In addition, it moved under the Commercial Courts Act. Specifically, it was seeking cancellation of Indian Patent No. IN 262697 granted to Novo Nordisk.
At 11:22 AM, shares of Natco Pharma were trading 11.63% higher at Rs 919.70 on NSE.
Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!
Click here to check market prediction for next trading session.
